However, in a recent study, metastatic NSCLC patients resistant to PD(L)‐1‐directed therapy were divided into three groups in a 1:1:1 ratio and received durvalumab plus tremelimumab alone or with the addition of low‐dose radiation every four cycles or hypofractionated RT only in the first cycle. This evidence concerns the gene CD274 and non-small cell lung carcinoma.